Research groups

GC16 Cellular biology in Hematology. Hypercoagulability

We are a consolidated group within IMIBIC. Our research focuses on Hematological Malignancies, allogeneic stem cell transplantation and hypercoagulability, and we are particularly interested in looking for new targets to improve or complement Leukemia treatments. Over the last years, we have accumulated plenty of knowledge in Acute Leukemias, particularly in Acute Myeloid Leukemia (AML) which is one of the most heterogeneous leukemia. Currently, in agreement with the Spanish Hematology Association (FEHH), we are studying several key somatic gene mutations and fusion genes in AML to perform the pattern of clonal evolution. In this sense, we are also generating a new panel of probes to sequence 50 genes in AML in collaboration with CIC in Salamanca. Our lab is one of the seven reference Spanish centers belonging to the PLATAFO-LAM of PETHEMA for the complete phenotypic and genomic characterization of AML at diagnosis and follow-up of Andalucia Hospitals.

We also routinely analyze the leukemic stem cell (LSC) enrichment in acute leukemia patients and intend to isolate the bona fide LSC by fluorescence-activated cell sorting (FACS) to develop functional assays. Furthermore, we study a type of B malignancy named Diffuse Large B-cell Lymphoma (DLBCL) within Non-Hodgkin Lymphoma. In this study, we are using an innovative technology for molecular classification of DLBCL by analysing a set of 20 genes in Nanostring platform and develop new personalized treatment strategies for the patients.

Another research area of our interest is immunotherapy applied to Leukemia, in specific, the immunological recovery of allogeneic hematolopoietic stem cell transplantation (Allo-HSCT). We have evidences that after Alo-SCT, leukemic specific T-cells are immunosurveillance patients’ body. Additionally, in collaboration with the University of Cordoba, we are generating a new protocol based on nanoscience for reprograming of T-cell against Leukemia. Moreover, Chronic graft-versus-host disease (cGvHD) is a late immune response of donor T and B against tissues recipient after Allo-HSCT and is the major cause of late morbidity and mortality. In attempt to elucidate new biomarkers in cGvHD to stop the progression or improve quality of patients’ life, we are analyzing gene expression profiling of T lymphocytes by Affymetrix microarrays to describe new pathways implicated in the pathophysiology of cGvHD.

Our clinical research activities include many clinical trials widely distributed in Acute leukemias, Lymphoma, Chronic Leukemia, Multiple Myeloma, Myelodysplastic and Myeloproliferative syndromes. We actively participate in various regional, national and international hematological networks such as PETHEMA, SEHOP, RESMD, and EBMT, increasing our collaborative network of leukemia researchers and clinicians. Our research has resulted in solid scientific production, contributing to improved clinical protocols and practices.

Research Lines

Networks

Keywords

  • Acute leukemia
  • lymphoma
  • allogenic stem cell transplantation
  • hypercoagulability

GC16 Cellular biology in Hematology. Hypercoagulability

Principal Investigator
Joaquín Sánchez García

Co-Principal Investigator
Francisco Velasco Gimena

Researchers
Victor Arqueros Martinez
Carmen Martin Calvo
Maria Del Carmen Martinez Losada
Jose Ramon Molina Hurtado
Rafael Rojas Contreras
Josefina Serrano López

Post-Doctoral Researcher
Juana Serrano Lopez

Clinical Researcher
Miguel Angel Alvarez Rivas
Francisco Javier Casaño Sanchez
Margarita Fernandez De La Mata
Estefania Garcia Torres
Antonia Rodriguez Villa
Salvador Tabares Carrasco

Technical Staff
Javier Dorado Pardo

Projects

Active in 2019

Regional

Serrano Lopez, J. Analysis of gene expression using a nanostring platform and of myd88-l265p mutation in paraffin-embedded samples for the personalised treatment of diffuse large B-cell lymphoma. Funding agency: Regional Ministry of Health and Social Policy (CISPS). Reference: PIN-0364-2016

Martínez Losada, C. Jornadas de investigación en hematología en Andalucía. Funding Agency: Asociación Andaluza de hematología y hemoterapia. Reference: AAHH2017_001            

National

García Torres, E. Effect of immunomodulators (lenadomide and pomalidomide) in lymphoid populations and their impact on the development of the disease. Funding Agency: Asociacion Andaluza de Hematologia y  Hemoterapia. Reference: AAHH2015_001

Finished projects

Sánchez García, J. Analysis of Phenotype, genotype, and sensitivity to new leukemia stem cell pharmaceutical products in LAM and LAL.Funding Agency: Sociedad Española de Hematología-Hemoterapia. Reference: FEHH15_001

Losada Martínez, C. Effect of immunomodulators (lenadomide and pomalidomide) in lymphoid populations and their impact on the development of the disease. Funding Agency: AAHH2016_001               

Publications

Publications 2019

Martinez-Cuadron D, Gil C, Serrano J, Rodriguez G, Perez-Oteyza J, Garcia-Boyero R, Jimenez-Bravo S, Vives S, Vidriales MB, Lavilla E, Perez-Simon JA, Tormo M, Colorado M, Bergua J, Lopez JA, Herrera P, Hernandez-Campo P, Gorrochategui J, Primo D, Rojas J; A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. LEUKEMIA RESEARCH. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006.
IF: 2,066
Q3

Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, Gonzalez-Campos J, Chillon M, Holowiecka A, Esteve J, Bergua J, Gonzalez-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernandez I, de la Serna J, Moreno MJ, Perez-Encinas M, K; An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. LEUKEMIA & LYMPHOMA. 2019 Apr;60(4):1030-1035. doi: 10.1080/10428194.2018.1516875.
IF: 2,674
Q: 3

Megias-Vericat JE, Martinez-Cuadron D, Lopez JM, Bergua JM, Tormo M, Serrano J, Gonzalez A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martinez AL, de la Fuente A, Amador ML, Hernandez-Rivas JA, Fernandez MA, Cervero CJ, Morino D, Campo PH, G; Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. 2019 Mar 1;11(1):e2019016. doi: 10.4084/MJHID.2019.016.
IF: 1,586
Q: 4

Garcia-Cadenas I, Yanez L, Jarque I, Martino R, Perez-Simon JA, Valcarcel D, Sanz J, Bermudez A, Munoz C, Calderon-Cabrera C, Garcia E, Alonso L, Suarez-Lledo M, Gonzalez Vicent M, Heras I, Viguria MC, Batlle M, Vazquez L, Lopez J, Solano C; Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). EUROPEAN JOURNAL OF HAEMATOLOGY. 2019 Jun;102(6):465-471. doi: 10.1111/ejh.13226.
IF: 2,217
Q: 3

Alonso L, Gonzalez-Vicent M, Belendez C, Badell I, Sastre A, Rodriguez-Villa A, Bermudez-Cortes M, Hladun R, de Heredia CD; Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). MEDICINA CLINICA. 2019 Feb 15;152(4):135-140. doi: 10.1016/j.medcli.2018.05.013.
IF: 1,277
Q: 3

Martos L, Fernandez-Pardo A, Lopez-Fernandez MF, Ibanez F, Herrero S, Tassies D, Gonzalez-Porras JR, Solmoirago MJ, Costa MJ, Reverter JC, Marco P, Roldan V, Lecumberri R, Velasco F, Oto J, Iruin G, Alonso MN, Vaya A, Bonanad S, Ferrando F, Marti E, Cid A; Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. THROMBOSIS AND HAEMOSTASIS. 2019 Sep;119(9):1409-1418. doi: 10.1055/s-0039-1692440. 
IF: 4,733
Q: 1

Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, Garcia E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, de la Calle GM, Manzur A, Marin JI, Marquez-Gomez I, Martin-Davila P, Mikulska M, Mon; Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ OPEN. 2019 May 24;9(5):e025744. doi: 10.1136/bmjopen-2018-025744.
IF: 2,413
Q: 2

Ribera JM, Garcia O, Moreno MJ, Barba P, Garcia-Cadenas I, Mercadal S, Montesinos P, Barrios M, Gonzalez-Campos J, Martinez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genesca E; Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. CANCER. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. 
IF: 6,102
Q: 1

Revilla N, Corral J, Minano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, Gonzalez-Lopez TJ, de la Morena-Barrio ME, Gonzalez-Porras JR, Vicente V, Lozano ML; Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. PLATELETS. 2019;30(6):743-751. doi: 10.1080/09537104.2018.1513476.
IF: 3,106
Q: 2

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germin; Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. LEUKEMIA & LYMPHOMA. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893.
IF: 2,674
Q: 3

Rodriguez-Veiga R, Montesinos P, Garcia E, Boluda B, Rojas R, Serrano J, Martinez-Cuadron D, Martin C, Sanz J, Tabares S, Pinana JL, Lorenzo I, Montoro J, Salavert M, Peman J, Jarque I, Solves P, Sanz GF, Torres A, Sanz MA; Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. MYCOSES. 2019 May;62(5):418-427. doi: 10.1111/myc.12891.
IF: 3,065
Q: 2

Bento L, Bastida JM, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martinez-Munoz ME, Fernandez-Aviles F, Roldan E, Chinea A, Yanez L, Zudaire T, Vaz CP, Espigado I, Lopez J, Valcarcel D, Duarte R, Cabrera R, Herrera C, Gonza. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant; Real life outcomes of patients aged >= 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. LEUKEMIA & LYMPHOMA. 2019 Nov;60(11):2720-2732. doi: 10.1080/10428194.2019.1607327.
IF: 2,674
Q: 3 

Main Publications 2018

Martinez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jerez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibanez M, Sempere A, Sanz MA, Lo-Coco F, Sanchez-Garcia J. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. HAEMATOLOGICA. 2018; 103(9):E400-E403.
IF: 9,09  
Q: 1   D: 1

Sanchez-Garcia J, Falantes J, Perez AM, Hernandez-Mohedo F, Hermosin L, Torres-Sabariego A, Bailen A, Hernandez-Sanchez JM, Rodriguez MS, Casano FJ, Calderon C, Labrador M, Vahi M, Serrano J, Lumbreras E, Hernandez-Rivas JM. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia. LEUKEMIA & LYMPHOMA. 2018; 59(5):1095-1104.
IF: 2,644  
Q: 2

Other Publications 2018

Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, Luque-Tevar M, Ruiz-Limon P, Barbarroja N, Jimenez-Gomez Y, Abalos-Aguilera MC, Collantes-Estevez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martinez C, Gonzalez-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, Lopez-Pedrera C. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. HAEMATOLOGICA. 2018; 103(5):908-918.
IF: 9,09  
Q: 1   D: 1

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2018; 24(8):1754-1758.
IF: 4,484  
Q: 1

de la Fuente FDA, Duran MS, Alvarez MA, Sanroman IL, Dios AM, Tamayo RR, Garcia R, Gonzalez MS, Prieto E, Barez A, Escalante F, Tejedor A, Ballesteros M, Cabanas V, Capote FJ, Couto C, Garzon S, Gonzalez-Pardo M, Manteca MVM. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. SEMINARS IN HEMATOLOGY. 2018; 55(4):189-196.
IF: 3,926  
Q: 2

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. BLOOD ADVANCES. 2018; 2(8):923-932.
IF: 0

Martinez-Cuadron D, Boluda B, Martinez P, Bergua J, Rodriguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordon L, Sempere A, Jimenez-Ubieto A, Prieto-Delgado J, Diaz-Beya M, Garrido A, Benavente C, Perez-Simon JA, Moscardo F, Sanz MA, Montesinos P. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. ANNALS OF HEMATOLOGY. 2018; 97(5):763-772.
IF: 2,845  
Q: 2

Serrano-Lopez J, Nattamai K, Pease NA, Shephard MS, Wellendorf AM, Sertorio M, Smith EA, Geiger H, Wells SI, Cancelas JA, Privette Vinnedge LM. 2.-Loss of DEK induces radioresistance of murine restricted hematopoietic progenitors. EXPERIMENTAL HEMATOLOGY  2018 Mar;59:40-50
IF: 2.436
Q: 2

Zhang C, D'Alessandro A, Wellendorf AM, Mohmoud F, Serrano-Lopez J, Perentesis JP, Komurov K, Alexe G, Stegmaier K, Whitsett JA, Grimes HL, Cancelas JA. 3.- KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia. ONCOTARGET 2018 Jul 3;9(51):29665-29679.
IF: 3,45
Q: 2

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. LEUK LYMPHOMA. 2019. Jan;60(1):246-249
IF: 2.644
Q: 2

Main Publications 2017

Martinez-Losada C, Martin C, Gonzalez R, Manzanares B, Garcia-Torres E, Herrera C. Patients lacking a Kir-ligand of HLA group C1 or C2 have a Better Outcome after Umbilical cord Blood Transplantation. FRONTIERS IN IMMUNOLOGY 2017.8():-810.
IF: 6,429
Q: 1

Paniagua JA, Bahamondes R, Cano-Sanchez A, Velasco F. Unexpected papilledema in a young male with Type 1 diabetes. CLINICAL CASE REPORTS. 2017.5(8):1333-1338.

Other Publications 2017

Perez-Sanchez C, Aguirre MA, Ruiz-Limon P, Abalos-Aguilera MC, Jimenez-Gomez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernandez-del Rio L, Gonzalez-Reyes JA, Segui P, Collantes-Estevez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, Lopez-Pedrera C. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile A Randomized, Placebo-Controlled Trial. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2017.37(10):1923-1932.
IF: 6,607
Q: 1  D: 1

Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Junca J, Malinverni R, Genesca E, Guardia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Sole F, Feliu E, Ribera JM, Spanish PETHEMA Group and the Spanish Society of Hematology. Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. GENES CHROMOSOMES & CANCER. 2017.56(11):810-820.
IF: 6,396
Q: 2 

Nomdedeu M, Pereira A, Ramos F, Valcarcel D, Costa D, Arnan M, Calvo X, Pomares H, Luno E, Diaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sanchez-Garcia J, Tormo M, Cedena MT, Nomdedeu B, Sanz G, Spanish MDS Grp. Excess mortality in the myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY. 2017.92(2):149-154.
IF: 5,275
Q: 1 

Kwon M, Bautista G, Balsalobre P, Sanchez-Ortega I, Montesinos P, Bermudez A, de Laiglesia A, Herrera P, Martin C, Humala K, Zabalza A, Torres M, Bento L, Corral LL, Heras I, Serrano D, Buno I, Anguita J, Regidor C, Duarte R, Cabrera R, Gayoso J, Diez-Martin JL. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. BONE MARROW TRANSPLANTATION. 2017.52(8):1138-1143.
IF: 3,874
Q: 2 

Garcia-Noblejas A, Cannata-Ortiz J, Conde E, Barca EB, Gutierrez N, Rojas R, Vidal MJ, Ramirez MJ, Jimenez-Ubieto A, Garcia-Ruiz JC, Sancho JM, Lopez A, Rull PR, Novelli S, Albo C, Deben G, Lopez-Guillermo A, Nicolas C, de Villambrosia SG, Mercadal S, Garcia-Sancho AM, Arranz R. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). ANNALS OF HEMATOLOGY. 2017.96(8):1323-1330.
IF: 3,083
Q: 2 

Sanz J, Kwon M, Bautista G, Sanz MA, Balsalobre P, Pinana JL, Solano C, Duarte R, Ferra C, Lorenzo I, Martin C, Barba P, Pascual MJ, Martino R, Gayoso J, Buno I, Regidor C, de la Iglesia A, Montoro J, Diez-Martin JL, Sanz GF, Cabrera R, on behalf of Grupo Español de Trasplante Hematopoyético (GETH). Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia. BLOOD ADVANCES. 2017.1(15):1047-1055.

Clinical Research

Active in 2019

Ensayo intergrupo para niños o adolescentes con LNH-B o LLA-B (LLA-L3): Evaluación de la eficacia y seguridad de Rituximab para pacientes de alto riesgo.
PI: Dr. José Ramón Molina Hurtado

Ofatumumab as part of the reduced intensity conditioning system (RIC) in patients at high risk of developing non-Hodgkin's lymphoma B receiving allogeneic hematopoietic stem cell transplantation.
PI: Dr. M Carmen Martín Calvo

Phase 3 randomized, double-blind, placebo-controlled study to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, recipients seropositive for cytomegalovirus (CMV) underwent allogeneic cells.
PI: Dr. Rafael Rojas Contreras

Multicenter phase IIIB study, international, open-label, single treatment group to assess the safety of obinutuzumab as a single agent or in combination with chemotherapy in patients with lymphatic leukemia relapsed / refractory chronic
PI: Dr. José Ramón Molina Hurtado

A randomized, double-blind, phase 3 study to assess the efficacy and safety of rituximab plus lenalidomide (CC-5013) vs. rituximab plus placebo in subjects with indolent relapsed / resistant lymphoma.
PI: Dr. Joaquín Sánchez García

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant.
PI: Dr. Miguel Angel Alvarez Rivas

A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients with high risk smoldering multiple myeloma (SMM) under 65 years.
PI: Dr. Miguel Angel Álvarez Rivas

Pilot study (Phase II) of combination pomalidomide / dexamethasone associated with low dose of cyclophosphamide in patients with refractory multiple myeloma who have received lenalidomide and bortezumib.
PI: Dr. Miguel Angel Álvarez Rivas

Observational Study to assess disease burden, in terms of health-related quality of life and direct healthcare costs, in patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant (ASCT) in Spain.
PI: Dr. Miguel Angel Álvarez Rivas

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL).
PI: Dr. Joaquín Sánchez García

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia.
PI: Dr. Josefina Serrano López

A Phase 20 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma.
PI: Dr. Joaquín Sánchez García

A Phase 3, Randomized, adaptive study comparing the efficacy and safety of defibrotide vs best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients undergoing hematopoietic stem cell transplant.
PI: Dr. M Carmen Martín Calvo

A Phase III Randomized Open-label Multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH3).
PI: Dr. Rafael Rojas Contreras

A Phase 3, Multicenter, Randomized, open-label study of guadecitabine (SGI-110) versus treatment choice in adults with previously treated acute myeloid leukemia.
PI: Dr. Josefina Serrano López

Estudio aleatorizado de fase III para comparar el trióxido de arsénico (ATO) combinado con ATRA e idarubicina frente a quimioterapia estándar basada en ATRA y antraciclinas (AIDA) en pacientes con leucemia promielocítica aguda de alto riesgo de nuevo diagnostico.
PI: Dr. Josefina Serrano López

Tratamiento de inducción con bortezomib, melfalán y prednisona (VMP) seguido de lenalidomida y dexametasona (Rd) frente a carfilzomib, lenalidomida y dexametasona (KRd) más/menos daratumumab, 18 ciclos, seguido de tratamiento de consolidación y mantenimiento con lenalidomida y daratumumab: un ensayo clínico de fase III, multicéntrico, aleatorizado para pacientes adultos mayores, de entre 65 y 80 años, con buen estado general y mieloma múltiple de nuevo diagnóstico.
PI: Dr. Miguel Angel Alvarez Rivas

Estudio fase III, aleatorizado, doble ciego, de quimioterapia de inducción (daunorrubicina o idarrubicina y citarabina) y de consolidación (dosis intermedias de citarabina) más midostaurina (PKC412) o de quimioterapia más placebo en pacientes con leucemia mieloide aguda (LMA) de nuevo diagnóstico sin mutaciones en FLT-3.
PI: Dr. Josefina Serrano López

Phase III Randomized double-blind, placebo-controlled study investigating the efficacy of the addition of crenolaninb to salvage chemotherapy alone in subjects less than 75 years of age with Relapsed/refractory FLT3 Mutated Acute  Leukemia.
PI: Dr. Josefina Serrano López

A randomized, doubled blinde, parallel-group, phase III study to compare the efficacy, safety and immunogenicity of proposed rituximab biosimilar (DRL-RI) with Mabthera in subjects with previously untreated , stage II-IV, cluster of differenciation (CD) 2.
PI: Dr. Joaquín Sánchez García

Estudio de fase 2, abierto y de un solo un grupo, del inhibidor de HDAC oral   abexinostat en pacientes con linfoma folicular en recaída o refractario.
PI: Dr. Joaquín Sánchez García

Open label phase 1 study to assess the maximum tolerated dose, pharmacokinetics, and safety of ixazomib adminitered intravenously to pediatric patients aged 0 to less than 18 years with relapse relapse or refractory acute lymphoblastic leukemia, with or w.
PI: Dr. José Ramón Molina Hurtado

Estudio de fase 1/1b de pevonedistat en combinación con azacitidina en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica o leucemia mielógenaguda con insuficiencia renal grave o insuficiencia hepática leve.
PI: Dr. Joaquín Sánchez García

Efficacy and safety of M281 in adults with warm autoimmune Hemolytic anemia: a multicenter, randomized, doble blind, placebo controlled study with a long-term open label extension.
PI: Dr. Víctor Arqueros Martínez

Estudio de la correlacióln entre la respuesta ex vivo a fármacos antineoplásicos y su eficacia en el tratamiento de la leucemia mieloide aguda.
PI: Dr. Josefina Serrano López

Trasplante de progenitores hematopoyéticos de donante haploidéntico con depleción selectiva in Vitro de linfocitos alo-reactivos, en pacientes con hemopatías malignas de alto riesgo. 
PI: Dr. María del Carmen Martín Calvo

Non-interventional post-authorization Registration patients with relapsed and refractory multiple myeloma treated with pomalidomide, who have received at least two prior treatments including lenalidomide and bortezomib, and who have experienced a proautologous hematopoietic stem cell transplant (VERSA STUDY)       
PI: Dr. Miguel Angel Álvarez Rivas

Estudio observacional prospectivo sobre la supervivencia global y la calidad de vida en pacientes de mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. Estudio SvLMA.
PI: Dr. Joaquín Serrano López

Impacto de la monitorización de enfermedad mínima residual mediante citometría de flujo en el manejo del mieloma múltiple.
PI: Dr. Miguel Angel Alvarez Rivas

Estudio Observacional retrospectivo sobre el tratamiento de linfoma de células del manto con Ibrutinib en la práctica clinica habitual.
PI: Dr. Joaquín Sánchez García

Patrones de tratamiento y resultados clínicos en vida real en pacientes unfit con Leucemia Mieloide Aguda tratados con una primera línea de tratamiento sistémico o con el mejor tratamiento de soporte. Estudio Current.
PI: Dr. Josefina Serrano López

Guía de recomendaciones de la SEHOP para el tratmiento de la leucemia libfoblástica aguda a bigenotípica del lactante menor de 1 año.
PI: Dr. José Ramón Molina Hurtado

Retrospective[EAC1]  no-intervencional post-authorization assessement of the use of Idelalisib in RR/CLL patients in Spain
PI: Dra. Fernandez de la Mata

Multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ibrutinib consolidation in combination with ofatumumab in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PI: Dra Fernandez de la Mata

Estudio observacional retrospectivo del tratamiento de la leucemia linfocítica crónica (LLC) con Ibrutinib en la práctica clínica habitual
PI: Dra Fernandez de la Mata

Members

Dr. Joaquín Sánchez García

Principal Investigator

Joaquin.sanchez.garcia.sspa@juntadeandalucia.es
Dr. Francisco Velasco Gimena

Co-Principal Investigator

Francisco.velasco.sspa@juntadeandalucia.es

Team

Victor Arqueros Martinez Carmen Martin Calvo Maria Del Carmen Martinez Losada Jose Ramon Molina Hurtado Rafael Rojas Contreras Josefina Serrano López Juana Serrano Lopez Miguel Angel Alvarez Rivas Francisco Javier Casaño Sanchez Margarita Fernandez De La Mata Estefania Garcia Torres Antonia Rodriguez Villa Salvador Tabares Carrasco Javier Dorado Pardo